centered image

centered image

India Variant Shows Resistance To Antibody Drugs, Vaccines

Discussion in 'Hospital' started by The Good Doctor, Jun 2, 2021.

  1. The Good Doctor

    The Good Doctor Golden Member

    Joined:
    Aug 12, 2020
    Messages:
    11,481
    Likes Received:
    6
    Trophy Points:
    12,195
    Gender:
    Female

    Antibody drugs and COVID-19 vaccines are less effective against a coronavirus variant that was first detected in India, researchers say. The variant, B.1.617.2, has mutations that make it more transmissible. It is now predominant in some parts of India and has spread to many other countries.

    Researchers from the Institut Pasteur and the European Hospital Georges Pompidou in Paris and at Orléans and Strasbourg Hospitals studied a B.1.617.2 variant isolated from a traveler returning from India. Compared to the B.1.1.7 variant first identified in Britain, the India variant was more resistant to antibody drugs, although three currently approved drugs still remained effective against it, they found.

    [​IMG]

    Antibodies in blood from unvaccinated COVID-19 survivors and from people who received both doses of the Pfizer/BioNTech vaccine were 3-fold to 6-fold less potent against the India variant than against the UK variant and a variant first identified in South Africa, according to a report posted on bioRxiv ahead of peer review.

    The two-dose AstraZeneca vaccine, which does not protect against the South Africa variant, is likely to be ineffective against the India variant as well, the authors said. Antibodies from people who had received their first dose "barely inhibited" this India variant, said study co-author Olivier Schwartz of Institut Pasteur.

    The study, Schwartz added, shows that the rapid spread of the India variant is associated with its ability to "escape" the effect of neutralizing antibodies.

    —Reuters Staff

    Source
     

    Add Reply

Share This Page

<